Back to Search
Start Over
[18F](2 S ,4 R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma.
- Source :
- Frontiers in Oncology; 10/12/2021, Vol. 11, p1-15, 15p
- Publication Year :
- 2021
-
Abstract
- The high glycolytic activity of multiple myeloma (MM) cells is the rationale for use of Positron Emission Tomography (PET) with <superscript>18</superscript>F-fluorodeoxyglucose ([<superscript>18</superscript>F]FDG) to detect both bone marrow (BM) and extramedullary disease. However, new tracers are actively searched because [<superscript>18</superscript>F]FDG-PET has some limitations and there is a portion of MM patients who are negative. Glutamine (Gln) addiction has been recently described as a typical metabolic feature of MM cells. Yet, the possible exploitation of Gln as a PET tracer in MM has never been assessed so far and is investigated in this study in preclinical models. Firstly, we have synthesized enantiopure (2 S ,4 R)-4-fluoroglutamine (4-FGln) and validated it as a Gln transport analogue in human MM cell lines, comparing its uptake with that of <superscript>3</superscript>H-labelled Gln. We then radiosynthesized [<superscript>18</superscript>F]4-FGln, tested its uptake in two different in vivo murine MM models, and checked the effect of Bortezomib, a proteasome inhibitor currently used in the treatment of MM. Both [<superscript>18</superscript>F]4-FGln and [<superscript>18</superscript>F]FDG clearly identified the spleen as site of MM cell colonization in C57BL/6 mice, challenged with syngeneic Vk12598 cells and assessed by PET. NOD.SCID mice, subcutaneously injected with human MM JJN3 cells, showed high values of both [<superscript>18</superscript>F]4-FGln and [<superscript>18</superscript>F]FDG uptake. Bortezomib significantly reduced the uptake of both radiopharmaceuticals in comparison with vehicle at post treatment PET. However, a reduction of glutaminolytic, but not of glycolytic, tumor volume was evident in mice showing the highest response to Bortezomib. Our data indicate that [<superscript>18</superscript>F](2 S ,4 R)-4-FGln is a new PET tracer in preclinical MM models, yielding a rationale to design studies in MM patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 2234943X
- Volume :
- 11
- Database :
- Complementary Index
- Journal :
- Frontiers in Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 153013194
- Full Text :
- https://doi.org/10.3389/fonc.2021.760732